C Number:	C98007
Lock Date:	12/18/2003
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
TDMSE Version:	1.9.1

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Sodium thioglycolate

MALE RATS

Organ	Morphology
Skin: Sebaceous Gland, Site of Application - Dermis	Hypertrophy
Skin: Site of Application - Epidermis	Hyperkeratosis
	Hyperplasia Diffuse

FEMALE RATS

Organ	Morphology
Skin: Sebaceous Gland, Site of Application - Dermis	Hypertrophy
Skin: Site of Application - Epidermis	Hyperkeratosis
	Hyperplasia Diffuse
	Parakeratosis Focal
	Ulcer Focal

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Adrenal Cortex: Zona Fasciculata Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	10/10 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
POLY-3 RATE (b)	10/10.00	0/0.00	0/0.00	0/0.00	0/0.00	10/10.00
POLY-3 PERCENT (g)	100%	0%	0%	0%	0%	100%
TERMINAL (d)	10/10 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Heart Cardiomyopathy						
LESION RATES						
OVERALL (a)	3/10 (30%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	3/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	30%	0%	0%	0%	0%	10%
TERMINAL (d)	3/10 (30%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.207N	(e)	(e)	(e)	(e)	P=0.293N
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.292N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.292N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.292N
LOGISTIC REGRESSION	P=0.207N	(e)	(e)	(e)	(e)	P=0.293N
COCH-ARM / FISHERS	P=0.201N	(e)	(e)	(e)	(e)	P=0.291N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Kidney **Nephropathy**						
LESION RATES						
OVERALL (a)	3/10 (30%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	3/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	30%	0%	0%	0%	0%	0%
TERMINAL (d)	3/10 (30%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	P=0.064N	(e)	(e)	(e)	(e)	P=0.111N
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.095N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.095N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.095N
LOGISTIC REGRESSION	P=0.064N	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.059N	(e)	(e)	(e)	(e)	P=0.105N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Kidney: Renal Tubule Regeneration Focal						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	20%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.380	(e)	(e)	(e)	(e)	P=0.500
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
LOGISTIC REGRESSION	P=0.380	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.377	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Liver **Hepatodiaphragmatic Nodule**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.309	(e)	(e)	(e)	(e)	P=0.500
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.304	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Liver **Inflammation Granulomatous**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Lung: Alveolus **Inflammation Chronic Focal**						
LESION RATES						
OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	0%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	P=0.138N	(e)	(e)	(e)	(e)	P=0.234N
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.227N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.227N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.227N
LOGISTIC REGRESSION	P=0.138N	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.132N	(e)	(e)	(e)	(e)	P=0.237N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Lymph Node: Thoracic **Hyperplasia Lymphoid**						
LESION RATES						
OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Sebaceous Gland, Site of Application - Dermis Hypertrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	2/10 (20%)	4/10 (40%)	5/10 (50%)	6/10 (60%)
POLY-3 RATE (b)	0/10.00	0/10.00	2/10.00	4/10.00	5/10.00	6/10.00
POLY-3 PERCENT (g)	0%	0%	20%	40%	50%	60%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	2/10 (20%)	4/10 (40%)	5/10 (50%)	6/10 (60%)
FIRST INCIDENCE	---	---	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P<0.001**	(e)	P=0.234	P=0.051	P=0.022*	P=0.009**
POLY 3	P<0.001**	(e)	P=0.227	P=0.033*	P=0.008**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.227	P=0.033*	P=0.008**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.227	P=0.033*	P=0.008**	P<0.001**
LOGISTIC REGRESSION	(e)	(e)	P=0.234	P=0.051	P=0.022*	P=0.009**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.237	P=0.043*	P=0.016*	P=0.005**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Site of Application - Epidermis Hyperkeratosis						
LESION RATES						
OVERALL (a)	0/10 (0%)	6/10 (60%)	9/10 (90%)	4/10 (40%)	4/10 (40%)	4/10 (40%)
POLY-3 RATE (b)	0/10.00	6/10.00	9/10.00	4/10.00	4/10.00	4/10.00
POLY-3 PERCENT (g)	0%	60%	90%	40%	40%	40%
TERMINAL (d)	0/10 (0%)	6/10 (60%)	9/10 (90%)	4/10 (40%)	4/10 (40%)	4/10 (40%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.509N	P=0.009**	P<0.001**	P=0.051	P=0.051	P=0.051
POLY 3	P=0.511N	P<0.001**	P<0.001**	P=0.033*	P=0.033*	P=0.033*
POLY 1.5	P=0.511N	P<0.001**	P<0.001**	P=0.033*	P=0.033*	P=0.033*
POLY 6	P=0.511N	P<0.001**	P<0.001**	P=0.033*	P=0.033*	P=0.033*
LOGISTIC REGRESSION	(e)	P=0.009**	P<0.001**	P=0.051	P=0.051	P=0.051
COCH-ARM / FISHERS	P=0.509N	P=0.005**	P<0.001**	P=0.043*	P=0.043*	P=0.043*
ORDER RESTRICTED	P=0.004**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.005**	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	VEHICLE CONTROL	11.25 MG/KG	22.5 MG/KG	45.0 MG/KG	90.0 MG/KG	180.0 MG/KG
Skin: Site of Application - Epidermis Hyperplasia Diffuse						
LESION RATES						
OVERALL (a)	0/10 (0%)	1/10 (10%)	2/10 (20%)	3/10 (30%)	5/10 (50%)	6/10 (60%)
POLY-3 RATE (b)	0/10.00	1/10.00	2/10.00	3/10.00	5/10.00	6/10.00
POLY-3 PERCENT (g)	0%	10%	20%	30%	50%	60%
TERMINAL (d)	0/10 (0%)	1/10 (10%)	2/10 (20%)	3/10 (30%)	5/10 (50%)	6/10 (60%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P<0.001**	P=0.500	P=0.234	P=0.111	P=0.022*	P=0.009**
POLY 3	P<0.001**	P=0.500	P=0.227	P=0.095	P=0.008**	P<0.001**
POLY 1.5	P<0.001**	P=0.500	P=0.227	P=0.095	P=0.008**	P<0.001**
POLY 6	P<0.001**	P=0.500	P=0.227	P=0.095	P=0.008**	P<0.001**
LOGISTIC REGRESSION	(e)	P=0.500	P=0.234	P=0.111	P=0.022*	P=0.009**
COCH-ARM / FISHERS	P<0.001**	P=0.500	P=0.237	P=0.105	P=0.016*	P=0.005**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Site of Application - Epidermis **Parakeratosis Focal**						
LESION RATES						
OVERALL (a)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	1/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	10%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	93 (T)	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
POLY 3	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
POLY 1.5	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
POLY 6	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	P=0.500	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.488N	P=0.500	(e)	(e)	(e)	(e)
ORDER RESTRICTED	P=0.353N	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.356N	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Site of Application - Epidermis **Ulcer Focal**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Spleen Congestion						
LESION RATES						
OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	10/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	100%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.309	(e)	(e)	(e)	(e)	P=0.500
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
LOGISTIC REGRESSION	P=0.309	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.304	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Spleen **Hematopoietic Cell Proliferation**						
LESION RATES						
OVERALL (a)	10/10 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
POLY-3 RATE (b)	10/10.00	0/0.00	0/0.00	0/0.00	0/0.00	10/10.00
POLY-3 PERCENT (g)	100%	0%	0%	0%	0%	100%
TERMINAL (d)	10/10 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Spleen Pigmentation						
LESION RATES						
OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	10/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	100%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.309	(e)	(e)	(e)	(e)	P=0.500
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
LOGISTIC REGRESSION	P=0.309	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.304	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Males			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Thymus: Thymocyte Atrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.309	(e)	(e)	(e)	(e)	P=0.500
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.304	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Thyroid Gland **Ectopic Thymus**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Adrenal Cortex: Zona Fasciculata Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Heart Cardiomyopathy						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	0%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	P=0.309N	(e)	(e)	(e)	(e)	P=0.500N
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
LOGISTIC REGRESSION	P=0.309N	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.304N	(e)	(e)	(e)	(e)	P=0.500N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Kidney Nephropathy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Kidney: Renal Tubule Regeneration Focal						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.138	(e)	(e)	(e)	(e)	P=0.234
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.227
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.227
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.227
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	P=0.234
COCH-ARM / FISHERS	P=0.132	(e)	(e)	(e)	(e)	P=0.237
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Liver **Hepatodiaphragmatic Nodule**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.138	(e)	(e)	(e)	(e)	P=0.234
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.227
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.227
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.227
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	P=0.234
COCH-ARM / FISHERS	P=0.132	(e)	(e)	(e)	(e)	P=0.237
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Females			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Liver **Inflammation Granulomatous**						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/10 (30%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	3/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	30%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/10 (30%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.207	(e)	(e)	(e)	(e)	P=0.293
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.292
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.292
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.292
LOGISTIC REGRESSION	P=0.207	(e)	(e)	(e)	(e)	P=0.293
COCH-ARM / FISHERS	P=0.201	(e)	(e)	(e)	(e)	P=0.291
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Lung: Alveolus **Inflammation Chronic Focal**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Lymph Node: Thoracic **Hyperplasia Lymphoid**						
LESION RATES						
OVERALL (a)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/3 (67%)
POLY-3 RATE (b)	0/1.00	0/0.00	0/0.00	0/0.00	0/0.00	2/3.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	66.7%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/3 (67%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.309	(e)	(e)	(e)	(e)	P=0.500
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.282	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Sebaceous Gland, Site of Application - Dermis Hypertrophy						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	6/10 (60%)	5/10 (50%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	2/10.00	6/10.00	5/10.00
POLY-3 PERCENT (g)	0%	0%	0%	20%	60%	50%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	6/10 (60%)	5/10 (50%)
FIRST INCIDENCE	---	---	---	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P<0.001**	(e)	(e)	P=0.234	P=0.009**	P=0.022*
POLY 3	P<0.001**	(e)	(e)	P=0.227	P<0.001**	P=0.008**
POLY 1.5	P<0.001**	(e)	(e)	P=0.227	P<0.001**	P=0.008**
POLY 6	P<0.001**	(e)	(e)	P=0.227	P<0.001**	P=0.008**
LOGISTIC REGRESSION	(e)	(e)	(e)	P=0.234	P=0.009**	P=0.022*
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P=0.237	P=0.005**	P=0.016*
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Site of Application - Epidermis Hyperkeratosis						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	7/10 (70%)	6/10 (60%)	5/10 (50%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	7/10.00	6/10.00	5/10.00
POLY-3 PERCENT (g)	0%	0%	10%	70%	60%	50%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	7/10 (70%)	6/10 (60%)	5/10 (50%)
FIRST INCIDENCE	---	---	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.003**	(e)	P=0.500	P=0.003**	P=0.009**	P=0.022*
POLY 3	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P=0.008**
POLY 1.5	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P=0.008**
POLY 6	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P=0.008**
LOGISTIC REGRESSION	(e)	(e)	P=0.500	P=0.003**	P=0.009**	P=0.022*
COCH-ARM / FISHERS	P=0.002**	(e)	P=0.500	P=0.002**	P=0.005**	P=0.016*
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Site of Application - Epidermis **Hyperplasia Diffuse**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	7/10 (70%)	8/10 (80%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	2/10.00	7/10.00	8/10.00
POLY-3 PERCENT (g)	0%	0%	0%	20%	70%	80%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	7/10 (70%)	8/10 (80%)
FIRST INCIDENCE	---	---	---	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P<0.001**	(e)	(e)	P=0.234	P=0.003**	P<0.001**
POLY 3	P<0.001**	(e)	(e)	P=0.227	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	P=0.227	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	P=0.227	P<0.001**	P<0.001**
LOGISTIC REGRESSION	(e)	(e)	(e)	P=0.234	P=0.003**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P=0.237	P=0.002**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Females			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Site of Application - Epidermis **Parakeratosis Focal**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	3/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	30%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P=0.111
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	P=0.111
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.105
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

			Females			
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Skin: Site of Application - Epidermis **Ulcer Focal**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	3/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	30%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
FIRST INCIDENCE	---	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P=0.111
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P=0.095
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	P=0.111
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.105
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Spleen Congestion						
LESION RATES						
OVERALL (a)	10/10 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
POLY-3 RATE (b)	10/10.00	0/0.00	0/0.00	0/0.00	0/0.00	10/10.00
POLY-3 PERCENT (g)	100%	0%	0%	0%	0%	100%
TERMINAL (d)	10/10 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Spleen **Hematopoietic Cell Proliferation**						
LESION RATES						
OVERALL (a)	10/10 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
POLY-3 RATE (b)	10/10.00	0/0.00	0/0.00	0/0.00	0/0.00	10/10.00
POLY-3 PERCENT (g)	100%	0%	0%	0%	0%	100%
TERMINAL (d)	10/10 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Spleen Pigmentation						
LESION RATES						
OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	10/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	100%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.309	(e)	(e)	(e)	(e)	P=0.500
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
LOGISTIC REGRESSION	P=0.309	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.304	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Thymus: Thymocyte Atrophy						
LESION RATES						
OVERALL (a)	4/10 (40%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/10 (30%)
POLY-3 RATE (b)	4/10.00	0/0.00	0/0.00	0/0.00	0/0.00	3/10.00
POLY-3 PERCENT (g)	40%	0%	0%	0%	0%	30%
TERMINAL (d)	4/10 (40%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/10 (30%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.410N	(e)	(e)	(e)	(e)	P=0.500N
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
LOGISTIC REGRESSION	P=0.410N	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.407N	(e)	(e)	(e)	(e)	P=0.500N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Thyroid Gland **Ectopic Thymus**						
LESION RATES						
OVERALL (a)	1/9 (11%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/9 (22%)
POLY-3 RATE (b)	1/9.00	0/0.00	0/0.00	0/0.00	0/0.00	2/9.00
POLY-3 PERCENT (g)	11.1%	0%	0%	0%	0%	22.2%
TERMINAL (d)	1/9 (11%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/9 (22%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.379	(e)	(e)	(e)	(e)	P=0.500
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
LOGISTIC REGRESSION	P=0.379	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.376	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**VEHICLE CONTROL**	**11.25 MG/KG**	**22.5 MG/KG**	**45.0 MG/KG**	**90.0 MG/KG**	**180.0 MG/KG**
Uterus Dilatation						
LESION RATES						
OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	4/10 (40%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	4/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	40%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	4/10 (40%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
LIFE TABLE	P=0.238	(e)	(e)	(e)	(e)	P=0.317
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.318
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.318
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.318
LOGISTIC REGRESSION	P=0.238	(e)	(e)	(e)	(e)	P=0.317
COCH-ARM / FISHERS	P=0.232	(e)	(e)	(e)	(e)	P=0.314
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are theP-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
(e)	Value of Statistic cannot be computed.
(g)	Poly-3 adjusted lifetime tumor incidence.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***